These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 39039998)

  • 21. Neuromuscular junction dysfunction in Lafora disease.
    Shukla M; Chugh D; Ganesh S
    Dis Model Mech; 2024 Oct; 17(10):. PubMed ID: 39301689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
    López-González I; Viana R; Sanz P; Ferrer I
    Mol Neurobiol; 2017 Jul; 54(5):3119-3130. PubMed ID: 27041370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy.
    Mitra S; Chen B; Wang P; Chown EE; Dear M; Guisso DR; Mariam U; Wu J; Gumusgoz E; Minassian BA
    Dis Model Mech; 2023 Jan; 16(1):. PubMed ID: 36511140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.
    Upadhyay M; Agarwal S; Bhadauriya P; Ganesh S
    Neurobiol Dis; 2017 Apr; 100():39-51. PubMed ID: 28063983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of skin biopsy for diagnosis in a case of Lafora disease.
    Rozenova KA; Lehman JS; Grande JP; Fine AL; Wieland CN
    J Cutan Pathol; 2022 Oct; 49(10):885-888. PubMed ID: 35708461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model.
    Mollá B; Heredia M; Campos Á; Sanz P
    Mol Neurobiol; 2022 Oct; 59(10):6018-6032. PubMed ID: 35835895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
    Valles-Ortega J; Duran J; Garcia-Rocha M; Bosch C; Saez I; Pujadas L; Serafin A; Cañas X; Soriano E; Delgado-García JM; Gruart A; Guinovart JJ
    EMBO Mol Med; 2011 Nov; 3(11):667-81. PubMed ID: 21882344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ontogeny of Lafora bodies and neurocytoskeleton changes in Laforin-deficient mice.
    Machado-Salas J; Avila-Costa MR; Guevara P; Guevara J; Durón RM; Bai D; Tanaka M; Yamakawa K; Delgado-Escueta AV
    Exp Neurol; 2012 Jul; 236(1):131-40. PubMed ID: 22542948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
    Rao SN; Sharma J; Maity R; Jana NR
    J Biol Chem; 2010 Jan; 285(2):1404-13. PubMed ID: 19892702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
    Augé E; Pelegrí C; Manich G; Cabezón I; Guinovart JJ; Duran J; Vilaplana J
    Glia; 2018 Oct; 66(10):2094-2107. PubMed ID: 30152044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
    Berthier A; Payá M; García-Cabrero AM; Ballester MI; Heredia M; Serratosa JM; Sánchez MP; Sanz P
    Mol Neurobiol; 2016 Mar; 53(2):1296-1309. PubMed ID: 25627694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora.
    Pellegrini P; Hervera A; Varea O; Brewer MK; López-Soldado I; Guitart A; Aguilera M; Prats N; Del Río JA; Guinovart JJ; Duran J
    Mol Neurobiol; 2022 Feb; 59(2):1214-1229. PubMed ID: 34962634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycogen hyperphosphorylation underlies lafora body formation.
    Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
    Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deciphering the role of malin in the lafora progressive myoclonus epilepsy.
    Romá-Mateo C; Sanz P; Gentry MS
    IUBMB Life; 2012 Oct; 64(10):801-8. PubMed ID: 22815132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway.
    Upadhyay M; Gupta S; Bhadauriya P; Ganesh S
    Biochem Biophys Res Commun; 2015 Aug; 464(1):106-11. PubMed ID: 26102034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic spine abnormalities correlate with behavioral and cognitive deficits in mouse models of Lafora disease.
    Taneja K; Ganesh S
    J Comp Neurol; 2021 Apr; 529(6):1099-1120. PubMed ID: 32785985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan.
    Sullivan MA; Nitschke S; Steup M; Minassian BA; Nitschke F
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in lafora progressive myoclonus epilepsy.
    Delgado-Escueta AV
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.